March 1, 2010
The risk of cardiac events drops sharply when HIV-positive smokers quit, mirroring what is seen in people not infected with the virus, according to preliminary data presented at the recent 17th Conference on Retroviruses and Opportunistic Infections.
The finding comes from the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study, which was designed to investigate cardiovascular risks associated with various HIV treatments. Kathy Petoumenos, PhD, of the University of New South Wales, and colleagues assessed risk of myocardial infarction; coronary heart disease, including MI; cardiovascular disease (CVD), including CHD and stroke; and all-cause mortality. The international cohort of 27,000 participants included 8,920 who had never smoked and served as a control.
Compared to the control group, previous smokers had a 73 percent increase in MI risk, a 60 percent increase in CHD risk and a 38 percent increase in CVD. Current smokers had a 3.4-fold elevated risk for MI, 2.5-fold for CHD, and 2.2-fold for CVD, respectively, compared to the control group. Current but not previous smokers had an increased risk for all-cause mortality.
Adapted from:
MedPage Today
02.19.2010; Michael Smith
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
| Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here. |